Helsinn and Riemser extend relationship in Germany

Published: 28-Sep-2011
Finance

Sign licensing agreement for drug to prevent chemotherapy induced vomiting


Swiss pharmaceutical firm Helsinn Healthcare has granted marketing rights in Germany to Riemser Arzneimittel for a next-generation treatment in development for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Riemser is the German licensee of Helsinn’s second-generation 5-HT3 receptor antagonist palonosetron,

The new product is a fixed-dose combination (in both oral and IV forms) containing netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron.

Under the terms of the agreement, Helsinn will handle all development activities (CMC, preclinical and clinical), obtaining regulatory approvals and holding the New Drug Application.

In addition, the firm will supply the product for commercial use in Germany.

  • Companies:
  • Helsinn Group
See more

You may also like

Research & Development

Helsinn invests €1 million in Gain Therapeutics

Read more
Swiss company will use the funding to address lysosomal storage disorders, CNS indications and additional diseases

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Helsinn invests €1 million in Gain Therapeutics

Swiss company will use the funding to address lysosomal storage disorders, CNS indications and additional diseases
Media

Helsinn Pharmaceuticals opens office in Shanghai, China

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, announced the approval of Helsinn Pharmaceuticals, Shanghai branch, by the Shanghai Administration for Industry and Commerce with a 30-year term
Research & Development

Helsinn Investment Fund leads financial round in GreenBone

New fund backed by the Helsinn Group, focused on supporting early stage opportunities in areas of high unmet patient need
Finance

Patient-driven innovations for cancer sufferers

Helsinn collaborates with Lyfebulb to support patient-driven innovations for people with cancer
Research & Development

Helsinn Group and MEI Pharma to develop acute myeloid leukaemia treatment

MEI Pharma to receive $20m, plus up to $444m in potential milestone payments as well as sales royalties
Research & Development

Helsinn grants rights to 5-HT3 product to Taiho

Potential new therapy for chemotherapy-induced nausea and vomiting
Manufacturing

Helsinn to build €15.4m cytotoxic plant in Switzerland

Will start commissioning laboratory projects in 2012
Subscribe now